Gita Suneja1, Matthew Boyer2, Baligh R Yehia2, Meredith S Shiels2, Eric A Engels2, Justin E Bekelman2, Judith A Long2. 1. University of Utah, Salt Lake City, UT; Marshall University, Huntington, WV; University of Pennsylvania; Veterans Affairs Center for Health Equity Research and Promotion, Philadelphia, PA; and National Cancer Institute, Bethesda, MD gita.suneja@icloud.com. 2. University of Utah, Salt Lake City, UT; Marshall University, Huntington, WV; University of Pennsylvania; Veterans Affairs Center for Health Equity Research and Promotion, Philadelphia, PA; and National Cancer Institute, Bethesda, MD.
Abstract
PURPOSE: HIV-infected individuals with non-AIDS-defining cancers are less likely to receive cancer treatment compared with uninfected individuals. We sought to identify provider-level factors influencing the delivery of oncology care to HIV-infected patients. METHODS: A survey was mailed to 500 randomly selected US medical and radiation oncologists. The primary outcome was delivery of standard treatment, assessed by responses to three specialty-specific management questions. We used the χ(2) test to evaluate associations between delivery of standard treatment, provider demographics, and perceptions of HIV-infected individuals. Multivariable logistic regression identified associations using factor analysis to combine several correlated survey questions. RESULTS: Our response rate was 60%; 69% of respondents felt that available cancer management guidelines were insufficient for the care of HIV-infected patients with cancer; 45% never or rarely discussed their cancer management plan with an HIV specialist; 20% and 15% of providers were not comfortable discussing cancer treatment adverse effects and prognosis with their HIV-infected patients with cancer, respectively; 79% indicated that they would provide standard cancer treatment to HIV-infected patients. In multivariable analysis, physicians comfortable discussing adverse effects and prognosis were more likely to provide standard cancer treatment (adjusted odds ratio, 1.52; 95% CI, 1.12 to 2.07). Physicians with concerns about toxicity and efficacy of treatment were significantly less likely to provide standard cancer treatment (adjusted odds ratio, 0.67; 95% CI, 0.53 to 0.85). CONCLUSION: Provider-level factors are associated with delivery of nonstandard cancer treatment to HIV-infected patients. Policy change, provider education, and multidisciplinary collaboration are needed to improve access to cancer treatment.
PURPOSE:HIV-infected individuals with non-AIDS-defining cancers are less likely to receive cancer treatment compared with uninfected individuals. We sought to identify provider-level factors influencing the delivery of oncology care to HIV-infectedpatients. METHODS: A survey was mailed to 500 randomly selected US medical and radiation oncologists. The primary outcome was delivery of standard treatment, assessed by responses to three specialty-specific management questions. We used the χ(2) test to evaluate associations between delivery of standard treatment, provider demographics, and perceptions of HIV-infected individuals. Multivariable logistic regression identified associations using factor analysis to combine several correlated survey questions. RESULTS: Our response rate was 60%; 69% of respondents felt that available cancer management guidelines were insufficient for the care of HIV-infectedpatients with cancer; 45% never or rarely discussed their cancer management plan with an HIV specialist; 20% and 15% of providers were not comfortable discussing cancer treatment adverse effects and prognosis with their HIV-infectedpatients with cancer, respectively; 79% indicated that they would provide standard cancer treatment to HIV-infectedpatients. In multivariable analysis, physicians comfortable discussing adverse effects and prognosis were more likely to provide standard cancer treatment (adjusted odds ratio, 1.52; 95% CI, 1.12 to 2.07). Physicians with concerns about toxicity and efficacy of treatment were significantly less likely to provide standard cancer treatment (adjusted odds ratio, 0.67; 95% CI, 0.53 to 0.85). CONCLUSION: Provider-level factors are associated with delivery of nonstandard cancer treatment to HIV-infectedpatients. Policy change, provider education, and multidisciplinary collaboration are needed to improve access to cancer treatment.
Authors: Frank J Palella; Rose K Baker; Anne C Moorman; Joan S Chmiel; Kathleen C Wood; John T Brooks; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Gita Suneja; Meredith S Shiels; Rory Angulo; Glenn E Copeland; Lou Gonsalves; Anne M Hakenewerth; Kathryn E Macomber; Sharon K Melville; Eric A Engels Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Malcolm V Brock; Craig M Hooker; Eric A Engels; Richard D Moore; Maura L Gillison; Anthony J Alberg; Jeanne C Keruly; Stephen C Yang; Richard F Heitmiller; Stephen B Baylin; James G Herman; Julie R Brahmer Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: J J Goedert; T R Coté; P Virgo; S M Scoppa; D W Kingma; M H Gail; E S Jaffe; R J Biggar Journal: Lancet Date: 1998-06-20 Impact factor: 79.321
Authors: Anna E Coghill; Ruth M Pfeiffer; Meredith S Shiels; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-06-15 Impact factor: 4.254
Authors: Keith M Sigel; Kimberly Stone; Juan P Wisnivesky; Lesley S Park; Chung Yin Kong; Michael J Silverberg; Sheldon Brown; Matthew Goetz; Maria C Rodriguez-Barradas; Cynthia Gibert; Fatma Shebl; Roger Bedimo; Roxanne Wadia; Joseph King; Kristina Crothers Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Kimberly L Levinson; David J Riedel; Laureen S Ojalvo; Wesley Chan; Ana M Angarita; Amanda N Fader; Anne F Rositch Journal: AIDS Date: 2018-01-14 Impact factor: 4.177
Authors: Joseph Lipscomb; Jeffrey M Switchenko; Christopher R Flowers; Theresa W Gillespie; Pascale M Wortley; A Rana Bayakly; Lyn Almon; Robyn Fernando; Kevin C Ward Journal: Leuk Lymphoma Date: 2019-12-18
Authors: Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels Journal: Cancer Date: 2019-05-03 Impact factor: 6.860
Authors: Amber Chi; Bryan E Adams; Joanna Sesti; Subroto Paul; Amber L Turner; David August; Darren Carpizo; Timothy Kennedy; Miral Grandhi; H Richard Alexander; Steven K Libutti; Stuart Geffner; Russell C Langan Journal: World J Surg Date: 2019-12 Impact factor: 3.352